Safety and efficacy of GP40071 compared with originator insulin aspart (NovoRapid < sup > ® < /sup > Penfill < sup > ® < /sup > ) in Type 1 diabetes mellitus

Conclusion: GP-Asp demonstrated similar safety and efficacy. Trial registration number: NCT04079413 (ClinicalTrials.gov).PMID:33928797 | DOI:10.2217/cer-2020-0208

Source: Journal of Comparative Effectiveness Research - April 30, 2021 Category: General Medicine Authors: Tatiana L Karonova Alexander Y Mayorov Maxim A Magruk Svetlana T Zyangirova Irina V Grigoryeva Oleg K Khmelnitski Anton Myshkovets Tatyana M Parfenova Anna A Mosikian Roman V Drai Source Type: research